title: Effectiveness and safety of rabbit anti-thymocyte globulin in Japanese patients with aplastic anemia.
abstract: Immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporine A is the standard treatment for aplastic anemia (AA). The ATG formulation in Japan was changed from horse ATG [Lymphoglobulin(®) (LG)] to rabbit ATG [Thymoglobulin(®) (TG)] in 2009. Since then, 12 patients with AA have been treated with TG. Here, we summarize the effectiveness and safety of TG in comparison with data from 14 AA patients treated with LG before April 2009. One subject treated with LG but none treated with TG terminated the treatment due to a grade III adverse effect. The overall 6-month response rate after IST was similar for LG and TG (67 and 75 %). Infection was noted in five (38 %) and four (33 %) subjects treated with LG and TG, respectively. The initial response rate was significantly higher in the early-treatment group treated within a year of diagnosis than in the late-treatment group, who were treated more than a year after diagnosis (85 vs. 29 %, respectively), as reported previously, without apparent differences between the LG and TG groups. We conclude that TG at a dose of 2.5 mg/kg/day for 5 days is effective and safe in Japanese patients with AA.
authors: Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan.
authors: Tatsuhiro
authors: T
authors: Sakamoto
authors: Naoshi
authors: N
authors: Obara
authors: Naoki
authors: N
authors: Kurita
authors: Mamiko
authors: M
authors: Sakata-Yanagimoto
authors: Hidekazu
authors: H
authors: Nishikii
authors: Yasuhisa
authors: Y
authors: Yokoyama
authors: Kazumi
authors: K
authors: Suzukawa
authors: Yuichi
authors: Y
authors: Hasegawa
authors: Shigeru
authors: S
authors: Chiba
mesh_terms: D000328:Adult; D000741:Anemia, Aplastic / Q000188:drug therapy* / Q000401:mortality; D000961:Antilymphocyte Serum / Q000008:administration & dosage* / Q000009:adverse effects; D044466:Asian People; D016572:Cyclosporine / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000961:Antilymphocyte Serum; D007136:Immunoglobulins; D007166:Immunosuppressive Agents; C515141:lymphoglobuline; D016572:Cyclosporine; C512542:thymoglobulin
references: Hematology Am Soc Hematol Educ Program. 2011;2011:76-81
references: 22160015
references: Br J Haematol. 2009 Oct;147(1):43-70
references: 19673883
references: Br J Haematol. 1999 Nov;107(2):330-4
references: 10583220
references: Int J Hematol. 2006 Aug;84(2):118-22
references: 16926132
references: Blood. 2003 Feb 15;101(4):1236-42
references: 12393680
references: Blood. 2012 Jun 7;119(23):5391-6
references: 22544699
references: Haematologica. 2007 Jan;92(1):11-8
references: 17229630
references: Leukemia. 2004 Mar;18(3):460-5
references: 14712285
references: Haematologica. 2011 Sep;96(9):1269-75
references: 21606164
references: Blood. 2006 Feb 15;107(4):1308-14
references: 16179371
references: Ann Hematol. 2013 Jun;92(6):817-24
references: 23318980
references: Int J Hematol. 2013 May;97(5):564-72
references: 23605367
references: Int J Hematol. 2011 Jun;93(6):832-837
references: 21617886
references: Br J Haematol. 2006 Jun;133(6):622-7
references: 16704436
references: Blood. 2006 Oct 15;108(8):2509-19
references: 16778145
references: Acta Haematol. 2000;103(1):16-8
references: 10705154
references: N Engl J Med. 2011 Aug 4;365(5):430-8
references: 21812672